yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
Cloud Expo & Virtualization 2009 East
Smarter Business Solutions Through Dynamic Infrastructure
Smarter Insights: How the CIO Becomes a Hero Again
Windows Azure
Why VDI?
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun's Incubation Platform: Helping Startups Serve the Enterprise
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Helix Announces Shareholder Approval for the Sale of Its Rivex Pharma Division to Pharmascience and Other Results of Its Annual General and Special Meeting

AURORA, ON -- (Marketwire) -- 01/24/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the "Shareholder Meeting") was held today as scheduled.

At the Shareholder Meeting, Helix received approval of 100% of the votes cast by shareholders present, in person or by proxy, for the special resolution approving the sale of its Rivex Pharma division to Pharmascience Inc. ("Pharmascience") for gross cash proceeds of up to $8.5 million, subject to adjustment (the "Rivex Transaction").

Robert Verhagen, Chief Executive Officer, said of the result, "We are pleased that Helix's shareholders have provided such a strong endorsement of the Rivex Transaction. The transaction will enable Helix to focus its management and financial resources on its cancer therapeutics products, including its ongoing clinical trial with L-DOS47, a drug candidate for treatment of non-small cell lung cancer." The Rivex Transaction was initially announced by Helix via news release on December 10, 2012 and remains subject to certain customary closing conditions. The transaction is expected to close on January 25, 2013.

Shareholders approved the election of William B. White, Robert A. Verhagen, Mario Gobbo, Marek Orlowski, Slawomir Majewski, John A. Rogers and Slawomir Ludwikowski as directors at the Shareholder Meeting. Shareholders also approved a special resolution approving an amendment to Helix's Articles moving Helix's registered office to Ontario.

KPMG LLP, Chartered Accountants, were appointed as auditors. However, a significant percentage of proxies received prior to the Shareholder Meeting withheld from voting on the appointment of auditors. The board of directors expects to meet with shareholders in the near future to better understand the reasons for this action, and the board will take appropriate action based on these discussions with shareholders.

At a board meeting held after the Shareholder Meeting, the newly-elected directors considered the structure of the board and the composition of the board committees. Mr. Gobbo was appointed as Chair of the new board.

"It has been a privilege to serve as Chair over the last ten months," said Mr. White. "Now that the business has stabilized, it is time to work on the next phase of Helix's development. I look forward to continuing my work as a director on the board."

"I thank Bill for his leadership," said Mr. Gobbo, "and I look forward to working with the board and management on the development and funding of Helix's proprietary technologies."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. Helix is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP."

Forward-Looking Statements and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, but not limited to, those relating to the completion of the Rivex Transaction, including the satisfaction of the conditions to closing the Rivex Transaction and the anticipated timelines for completing the Rivex Transaction. Forward-looking statements, which may be identified by words including, without limitation, "will", "may", "subject", "expects", and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) that the Rivex Transaction is not completed on the anticipated timelines or at all; (ii) that the conditions precedent set forth in the Purchase Agreement, are not satisfied by either or both of Helix or Pharmascience, or waived, within the timelines required by the Purchase Agreement; (iii) changes in market, economic, industry or regulatory conditions; and (iv) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators under Helix's profile on SEDAR at (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations:
Helix BioPharma Corp.
Tel: 905 841-2300

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT or...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys ...
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any ot...
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers